289656-82-2

Basic information

• Product Name: BIS-(4-FLUORO-PHENYL)-PHENYL-ACETONITRILE
• Synonyms: BIS-(4-FLUORO-PHENYL)-PHENYL-ACETONITRILE;Benzeneacetonitrile, 4-fluoro-a-(4-fluorophenyl)-a-phenyl-
• CAS NO: 289656-82-2
• Molecular Formula: C20H13F2N
• Molecular Weight: 305.32
• Mol File: 289656-82-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 389.5°C at 760 mmHg
• Flash Point: 189.4°C
• Appearance: /
• Density: 1.215g/cm³
• Vapor Pressure: 2.83E-06mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: 2-8°C
• CAS DataBase Reference: BIS-(4-FLUORO-PHENYL)-PHENYL-ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: BIS-(4-FLUORO-PHENYL)-PHENYL-ACETONITRILE(289656-82-2)
• EPA Substance Registry System: BIS-(4-FLUORO-PHENYL)-PHENYL-ACETONITRILE(289656-82-2)

Safety Data

• Hazardous Substances Data: 289656-82-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C20H13F2N/c21-18-10-6-16(7-11-18)20(14-23,15-4-2-1-3-5-15)17-8-12-19(22)13-9-17/h1-13H

Upstream product

• 379-55-5 bis(4-fluorophenyl)phenylmethanol 
• 75-36-5 acetyl chloride 
• 100-58-3 phenylmagnesium bromide 
• 7677-24-9 trimethylsilyl cyanide 
• 345-92-6 4,4'-Difluorobenzophenone 
• 379-54-4 bis(4-fluorophenyl)phenylchloromethane 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 289656-45-7 Senicapoc 
• 386-95-8 bis-(4-fluoro-phenyl)-phenyl-methane 
• 1391151-86-2 C₂₀H₁₄F₂O₂ 

Relevant articles and documents

Process development and optimization for production of a potassium ion channel blocker, ICA-17043

A scalable process for the manufacture of a potassium ion channel blocker was developed and optimized. Key features of the process include an optimized Grignard reaction, a direct cyanation of the intermediate trityl alcohol derivative, and an improved nitrile hydrolysis protocol, relative to the original acidic hydrolysis conditions, to generate the crude active pharmaceutical ingredient (API) with >95% HPLC purity. The Grignard and the cyanation reactions could be telescoped, resulting in an improved throughput compared to the original four-step process. An effective recrystallization of the API was also developed and the process scaled up to manufacture multiple batches at the pilot scale.

TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS

The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The com